Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Mechanism of potential acolbifene toxicity studied
May 12th, 2005
According to a study from the United States, "Although approved for the treatment of hormone-dependent breast cancer as well as for the prevention of breast cancer in high-risk women, the selective estrogen receptor modulator (SERM) tamoxifen has been associated with an increased risk of endometrial cancer in women. "With an understanding of the potential carcinogenic mechanisms of these compounds, SERMs could in principle be designed or selected for use that avoids these problems." J. Liu and colleagues, University of Illinois, explained, "Acolbifene (EM-652) is a fourth-generation SERM and the active form of the ester prodrug EM-800. As a pure...
Source: Women's Health Weekly (2005-05-12)
|
